{"disease":{"id":"severe-hypertriglyceridemia","name":"severe hypertriglyceridemia"},"drugs":{"marketed":[{"drug_id":"omega","indication_name":"Severe Hypertriglyceridemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"omega","company_name":"Gachon University Gil Medical Center","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"omega-3","indication_name":"Severe Hypertriglyceridemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omega 3","company_name":"Assiut University","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":14,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05079919","title":"A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":617,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03001817","title":"Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":551,"lead_sponsor_name":"Kowa Research Institute, Inc.","has_results":true},{"nct_id":"NCT03011450","title":"Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":471,"lead_sponsor_name":"Kowa Research Institute, Inc.","has_results":true},{"nct_id":"NCT05552326","title":"A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":446,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05883865","title":"Safety Study of Fenofibrate During Pregnancy","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"First People's Hospital of Hangzhou","has_results":false},{"nct_id":"NCT04720534","title":"Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":229,"lead_sponsor_name":"Arrowhead Pharmaceuticals","has_results":true},{"nct_id":"NCT05355402","title":"A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04541186","title":"Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"89bio, Inc.","has_results":true},{"nct_id":"NCT06555640","title":"A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"Zhejiang Doer Biologics Co., Ltd.","has_results":false},{"nct_id":"NCT03452228","title":"Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT06500598","title":"Compassionate Use of Evinacumab","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT06796426","title":"Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Arrowhead Pharmaceuticals","has_results":false}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}